Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas

Neurosurgery

Volumn 41, Issue 5, 1997, Pages 1028-1038

  Kowalczuk, Andrew ^a   Loch Macdonald, R ^b   Amidei, Chris ^b   Dohrmann III, George ^c   Erickson, Robert K ^d   Hekmatpanah, Javad ^d   Krauss, Stuart ^a   Krishnasamy, Swarna ^b   Masters, Gregory ^b   Mullan, Sean F ^c   Mundt, Arno J ^d   Sweeney, Patrick ^d   Yokes, Everett E ^d   Weir, Bryce K A ^c   Wollman, Robert L ^b  

^a Section of Neurosurgery   (United States)

^b Department of Radiation and Cellular Oncology ^*  (United States)

^c SECTION OF HEMATOLOGY ONCOLOGY   (United States)

^d UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Brain neoplasm; Cytoreductive surgery; Malignant glioma; Outcome; Prognostic factor; Radiation therapy

Indexed keywords

ADULT; AGE; AGED; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ASTROCYTOMA; BRAIN NEOPLASMS; FEMALE; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RETROSPECTIVE STUDIES; SEIZURES; SURVIVAL RATE; TIME FACTORS;

EID: 0030707622     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006123-199711000-00004     Document Type: Article

References (64)

1. Albert FK, Foisting M, Sartor K, Adams HP, Kunze S: Early postoperative magnetic resonance imaging after resection of malignant glioma: Objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery 34:45-61,1994.
2. Ammirati M, Vick N, Liao Y, Ciric I, Mikhael M: Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas. Neurosurgery 21:201-206, 1987.
3. Andreou J, George AE, Wise A, de Leon M, Kricheff II, Ransohoff J, Foo SH: CT prognostic criteria of survival after malignant glioma surgery. AJNR Am J Neuroradiol 4:488-490,1983.
4. Apuzzo MLJ: Survival after stereotactic biopsy of malignant gliomas. Neurosurgery 22:472-473,1988 (comment).
5. Ayoubi S, Walter PH, Naik S, Sankaran M, Robinson D: Audit in the management of gliomas. Br J Neurosurg 7:61-69,1993.
6. Barker FG, Prados MD, Chang SM, Gutin PH, Lamborn KR, Larson DA, Malec MK, McDermott MW, Sneed PK, Wara WM, Wilson CB: Radiation response and survival time in patients with glioblastoma multiforme. J Neurosurg 84:442-448,1996.
7. Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G, Muller P, Morawetz R, Schold SC: Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 345:1008-1012,1995.
8. Buatti JM, Marcus RB, Mendenhall WM, Friedman WJ, Bova FJ: Accelerated hyperfractionated radiotherapy for malignant gliomas. Int J Radial Oncol Biol Phys 34:785-792,1996.
9. Coffey RJ, Lunsford LD, Taylor FH: Survival after stereotactic biopsy of malignant gliomas. Neurosurgery 22:465-473, 1988.
10. Cohadon F, Aovad N, Rougier A, Vital C, Rivel J, Dartigues JS: Histologie and non-histologic factors correlated with survival time in supratentorial astrocytic tumors. J Neurooncol 3:103-111,1985.
11. Cox DR: Regression models and life-tables. J R Stat Soc (B) 34:187-220,1972.
12. Cox DR: Partial likelihood. Biometrika 62:269-276,1975.
13. Curran WJ Jr., Scott CB, Horton J, Nelson JS, Weinstein AS, Nelson DF, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Powlis WD: Does extent of surgery influence outcome for astrocytoma with atypical or anaplastic foci (AAF)? A report from three Radiation Therapy Oncology Group (RTOG) trials. J Neurooncol 12:219-227, 1992.
14. Devaux BC, O'Fallon Jr., Kelly PJ: Resection, biopsy, and survival in malignant glial neoplasms: A retrospective study of clinical parameters, therapy, and outcome. J Neurosurg 78:767-775,1993.
15. Dinapoli RP, Brown LD, Arusell RM, Earle JD, O'Fallon Jr., Buckncr JC, Scheilhauer BW, Krook JE, Tschetter LK, Maier JA, Pfeifle DM, Gcsme DH: Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma. J Clin Oncol 11:1316-1321,1993.
16. Duncan GG, Goodman GB, Ludgate CM, Rheaume DE: The treatment of adult supratentorial high grade astrocytomas. J Neurooncol 13:63-72,1992.
17. European Organization for Research on Treatment of Cancer (EORTC) Brain Tumor Group: Effect of CCNU on survival rate of objective remission and duration of free interval in patients with malignant brain glioma: Final evaluation. Eur J Cancer 14:851-856,1978.
18. European Organization for Research on Treatment of Cancer (EORTC) Brain Tumor Group: Evaluation of CCNU, VM-26 plus CCNU, and procarbazine in supratentorial brain gliomas: Final evaluation of a randomized study. J Neurosurg 55:27-31, 1981.
19. Eyre HJ, Quagliana JM, Eltringham Jr., Frank J, O'Bryan RM, McDonald B, Rivkin SE: Randomized comparisons of radiotherapy and CCNU versus radiotherapy, CCNU plus procarbazine for the treatment of malignant gliomas following surgery: A Southwest Oncology Group report. J Neurooncol 1:171-177,1983.
20. Fischbach AJ, Martz KL, Nelson JS, Griffin TW, Chang CH, Horton J, Nelson DF: Long-term survival in treated anaplastic astrocytomas: A report of combined RTOG/ECOG studies. Am J Clin Oncol 14:365-370, 1991.
21. Franklin CI: Does the extent of surgery make a difference in high grade malignant astrocytoma? Australas Radiol 36:44-47,1992.
22. Ganju V, Jenkins RB, O'Fallon Jr., Scheithauer BVV, Ransom DT, Katzmann JA, Kimmel DVV: Prognostic factors in gliomas: A multivariate analysis of clinical, pathologic, flow cytometric, cytogenic, and molecular markers. Cancer 74:920-927,1994.
23. Grambsch PM, Therneau TM: Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81:515-526, 1993.
24. Green SB, Byar DP, Walker MD, Pistenmaa DA, Alexander E Jr., Batzdorf U, Brooks VVH, Hunt WE, Mealy J Jr., Odom GL, Paoletti P, Ransohoff J, Robertson JT, Selker RG, Shapiro WR, Smith KR Jr., Wilson CB, Strike TA: Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep 67:121-132, 1983.
25. Hall WA, Djalilian HR, Sperduto PW, Cho KH, Gerbi BJ, Gibbons JP, Rohr M, Clark HB: Stereotactic radiosurgery for recurrent malignant gliomas. J Clin Oncol 13:1642-1648,1995.
26. Halperin EC, Burger PC, Bullard DE: The fallacy of the localized supratentorial malignant glioma. Int J Radiât Oncol Biol Phys 15:505-509, 1988.
27. Halperin EC, Herndon J, Schold SC, Brown M, Vick N, Cairncross JG, Macdonald DR, Caspar L, Fischer B, Dropcho E, Rosenfeld S, Morawetz R, Piepmeier J, Hait W, Byrne T, Salter M, Imperato J, Khandekar J, Paleologos N, Burger P, Bentel GC, Friedman A: A Phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain. Int J Radiât Oncol Biol Phys 34:793-802, 1996.
28. Hirakawa K, Suzuki K, Ueda S, Nakagawa Y, Yoshino E, Ibayashi N, Hayashi K: Multivariate analysis of factors affecting postoperative survival in malignant astrocytoma: Importance of DNA quantification. J Neurooncol 2:331-340, 1984.
29. Huber A, Beran H, Becherer A, Prosenc N, Witzmann A: Supratentorial glioma: Analysis of clinical and temporal parameters in 163 cases [in German]. Neurochirurgia 36:189-193.
30. lacoangeli M, Roselli R, Prezioso A, Scerrati M, Rossi GF: Staging of supratentorial hemispheric glioma using lumour extension, histopathological grade, and extent of surgical resection. Br J Surg 80:1130-1133,1993.
31. Jeremic B, Grujicic D, Antunovic V, Djuric L, Shibamoto Y: Accelerated hyperfractionated radiation therapy for malignant glioma: A Phase II study. Am J Clin Oncol 18:449-453, 1995.
32. Jeremic B, Grujicic D, Antunovic V, Djuric L, Stojanovic M, Shibamoto Y: Hyperfractionated radiotherapy (HFX RT) followed by multiagent chemotherapy (CHT) in patients with malignant glioma: A Phase II study. Int J Radiât Oncol Biol Phys 30:1179-1185,1994.
33. Kaplan EL, Meier P: Nonparametric estimations from incomplete observations. J Am Slat Assoc 53:457-481,1958.
34. Karnosfsky DA, Burchenal HH, Armistead GC: Triethylene melamine in the treatment of neoplastic disease: A compound with nitrogen-mustard-like activity suitable for oral or intravenous use. AMA Arch Int Med 87:477-516, 1951.
35. Kinsella TJ, Collins J, Rowland J, Klecker RJ, Wright D, Katz D, Steinberg SM, Glastein E: Pharmacology and Phase I/II study of continuous intravenous infusions of iododeoxyuridine and hyperfractionated radiotherapy in patients with glioblastoma multiforme. J Clin Oncol 6:871-879, 1988.
36. Kliehues P, Burger PC, Scheithauer BW: The new WHO classification of brain tumors. Brain Pathol 3:255-268,1993.
37. Kreth FW, Warnke PC, Scheremet R, Ostertag CB: Surgical resection and radiation therapy versus biopsy and radiation therapy in the treatment of glioblastoma multiforme. J Neurosurg 78:762-766,1993.
38. Krishnasamy S, Yokes EE, Dohrmann GJ, Mick R, Garcia JC, Kolker JD, Wollman RL, Hekmatpanah J, Weischelbaum RR: Concomitant chemoradiotherapy, neutron boost, and adjuvant chemotherapy for anaplastic astrocytoma and glioblastoma multiforme. Cancer Invest 13:453-459, 1995.
39. Levin VA, Maor MH, Thall PF, Yung VVK, Bruner J, Sawaya R, Kyritsis AP, Leeds N, Woo S, Rodriguez L: Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme. Int J Radial Oncol Biol Phys 33:357-364,1995.
40. Masciopinto JE, Levin AB, Mehta MP, Rhode BS: Stereotactic radiosurgery for glioblastoma multiforme. Stereotact Funct Neurosurg 63:233-240, 1994.
41. Medical Research Council Brain Tumour Working Party: Prognostic factors for high-grade malignant glioma: Development of a prognostic index. J Neurooncol 9:47-55, 1990.
42. Mehta MP, Masciopinto J, Rozental J, Levin A, Chappell R, Bastin K, Miles J, Turski P, Kubsad S, Mackie T, Kinsella T: Stereotactic radiosurgery for glioblastoma multiforme: Report of a prospective study evaluating prognostic factors and analyzing long-term survival advantage. Int J Radial Oncol Biol Phys 30:541-549, 1994.
43. Miller PJ, Hassanein RS, Giri PCS, Kimler BF, O'Boynick P, Evans RG: Univariate and multivariate statistical analysis of high-grade gliomas: The relationship of radiation dose and other prognostic factors. Int J Rad Oncol Biol Fhys 19:275-280, 1990.
44. Murovic J, Turowski K, Wilson CB, Hoshino T, Levin V: Computerized tomography in the prognosis of malignant cerebral gliomas. J Neurosurg 65:799-806, 1986.
45. Nazzaro JM, Neuwelt EA: The role of surgery in the management of supratentorial intermediate and high-grade astrocytomas in adults. J Neurosurg 73:331-344, 1990.
46. Nelson DF, Diener-West M, Weinstein AS, Schoenfeld D, Nelson JS, Sause WT, Chang CH, Goodman R, Carabell S: A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: Final report of an RTOG study. Int J Radial Oncol Biol Fhys 12:1793-1800, 1986.
47. Phillips TL, Levin VA, Ahn DK, Gutin PH, Davis RL, Wilson CB, Prados MD, Wara WM, Flam MS: Evaluation of bromodeoxyuridine in glioblastoma multiforme: A Northern California Cancer Center Phase II study. Int J Radiât Oncol Biol Phys 21:709-714,1991.
48. Prados MD, Gutin PH, Phillips TL, Wara WM, Larson DA, Sneed PK, Davis RL, Ahn DK, Lambom K, Wilson CB: Highly anaplastic astrocytoma: A review of 357 patients treated between 1977 and 1989. Int J Radial Oncol Biol Phys 23:3-8,1992.
49. Quigley MR, Maroon JC: The relationship between survival and the extent of resection in patients with supratentorial malignant gliomas. Neurosurgery 29:385-389,1991.
50. Rostomily RC, Spence AM, Duong D, McCormick K, Bland M, Berger MS: Multimodality management of recurrent adult malignant gliomas: Results of a Phase II multiagent chemotherapy study and analysis of cytoreductive surgery. Neurosurgery 35: 378-388, 1994.
51. Sandberg-Wollheim M, Malmstrom P, Stromblad LG, Anderson H, Borgstrom S, Brun A, Cronqvist S, Hougard K, Salford LG: A randomized study of chemotherapy with procarbazine, vincristine, and lomustine with and without radiation therapy for astrocytoma Grades 3 and 4. Cancer 68:22-29, 1991.
52. Sarkaria JN, Mehta MP, Loeffler JS, Buatti JM, Chappell RJ, Levin AB, Alexander E III, Friedman WA, Kinsella TJ: Radiosurgery in the initial management of malignant gliomas: Survival comparison with the RTOG recursive partitioning analysis. Int J Radiât Oncol Biol Phys 32:931-941,1995.
53. Scharfen CO, Sneed PK, Wara WM, Larson DA, Phillips TL, Prados MD, Wearver KA, Malec M, Acord P, Lamborn KR, Lamb SA, Ham B, Gutin PH: High activity iodine-125 interstitial implant for gliomas. Int J Radial Oncol Biol Phys 24:583-591, 1992.
54. Shapiro WR, Green SB, Burger PC, Mahaley MS Jr., Selker RG, VanGilder JC, Robertson JT, Ransohoff J, Mealy J Jr., Strike TA, Pistenmaa DA: Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant gliomas: Brain tumor cooperative group trial 8001. J Neurosurg 71:1-9,1989.
55. Simpson Jr., Horton J, Scott C, Curran WJ, Rubin P, Fischbach J, Isaacson S, Rotman M, Asbell SO, Nelson JS, Weinstein AS, Nelson DF: Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: Results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radial Oncol Biol Phys 26:239-244, 1993.
56. Sneed PK, Larson DA, Gutin PH: Brachytherapy and hyperthermia for malignant astrocytomas. Semin Oncol 21:186-197,1994.
57. Sneed PK, Prados MD, McDermott MW, Larson DA, Malec MK, Lamborn KR, Davis RL, Weaver KA, Wara WM, Phillips TL, Gutin PH: Large effect of age on the survival of patients with glioblastoma treated with radiotherapy and brachytherapy boost. Neurosurgery 36:898-904,1995.
58. Sofietti R, Chio A, Giordana MT, Ruda R, Sales S, Vasario E, Schiffer D: Prognostic factors in anaplastic astrocytomas after surgery and conventional radiotherapy, in Paoletti P, Takakura K, Walker MD, Butti G, Pezotta S (eds): Neuro-Oncology. Amsterdam, Kluwer Academic Publishers, 1991, pp 179-180.
59. Sullivan F], Herscher LL, Cook JA, Smith J, Steinberg SM, Epstein AH, Oldfield EH, Goffman TE, Kinsella TJ, Mitchell JB, Glastein E: National Cancer Institute (Phase II) study of high-grade glioma treated with accelerated hyperfractionated radiation and iododeoxyuridine: Results in anaplastic astrocytoma. Int J Radiât Oncol Biol Phys 30:583-590,1994.
60. Vecht CJ, Avezaat CJ, van Putten WL, Eijkenboom WMH, Stefanko SZ: The influence of the extent of surgery on the neurological function and survival in malignant glioma: A retrospective analysis in 243 patients. J Neurol Neurosurg Psychiatry 53:466-471,1990.
61. Watne K, Hannisdal E, Nome O, Hager B, Hirschberg H: Prognostic factors in malignant gliomas with special reference to intraarterial chemotherapy. Acta Oncol 32:307-310, 1993.
62. Weir B: The relative prognostic significance of factors affecting postoperative survival in astrocytomas, Grades 3 and 4. J Neurosurg 38:448-452,1973.
63. Winger MJ, Macdonald DR, Cairncross JG: Supratentorial anaplastic gliomas in adults. J Neurosurg 71:487-493, 1989.
64. Wood Jr., Green SB, Shapiro WR: The prognostic importance of tumor size in malignant gliomas: A computed tomographic scan study by the Brain Tumor Cooperative Group. J Clin Oncol 6:338-343, 1988.